GLP-1 Drugs and Gallbladder Disease: Understanding the Acute Cholecystitis Risk | Research

The takeaway

Review examines the association between GLP-1 receptor agonists and acute cholecystitis, discussing mechanisms and clinical implications for the millions taking these drugs.

Small but real risk
GLP-1 drugs slightly increase acute cholecystitis risk, primarily through rapid weight loss-induced bile changes

What the researchers found

GLP-1 drugs carry a small but real increased risk of acute cholecystitis, primarily through rapid weight loss-induced bile changes and possible direct effects on gallbladder motility.

Why it matters

Acute cholecystitis requires emergency treatment and often surgery. With millions on GLP-1 drugs, understanding and managing this risk is essential for patient safety.

The numbers in context

One 66-year-old female patient. Acute cholecystitis developed within 72 hours of the procedure.

How the study worked

Review of clinical evidence and mechanisms linking GLP-1 RA use to acute cholecystitis risk.

Who was studied

66-year-old female on semaglutide for obesity

What this study cannot tell us

Short review. Absolute risk increase is small. Difficult to separate drug-specific from weight loss-associated risk. Individual risk factors (pre-existing gallstones, female sex) matter.

How to read the evidence

Moderate evidence: review of clinical data showing consistent gallbladder risk signal across multiple GLP-1 drugs and trials.

When this study was published

Published in 2025. Addresses a recognized safety concern for GLP-1 drug users.

The bigger picture

Gallbladder events are a recognized complication of rapid weight loss from any cause — bariatric surgery patients face similar risks. Understanding that this is primarily a weight-loss effect rather than a direct drug effect helps contextualize the risk for GLP-1 drug users.

Questions still open

Should patients on GLP-1 drugs receive gallbladder ultrasound screening?
Does ursodiol prophylaxis reduce gallstone risk during GLP-1-induced weight loss?
Are some GLP-1 drugs less likely to cause gallbladder events than others?

Common questions

Do GLP-1 drugs cause gallbladder problems?

There is a small but real increased risk of gallstones and gallbladder inflammation (cholecystitis) with GLP-1 drugs. This is primarily due to rapid weight loss — the same risk exists after bariatric surgery. The overall risk is low, but watch for right upper abdominal pain.

Should I be worried about my gallbladder on semaglutide?

The absolute risk is small. Most patients have no gallbladder problems. However, if you experience sudden right upper abdominal pain, especially after meals, seek medical attention. Risk factors include rapid weight loss, female sex, and pre-existing gallstones.

Read the original research

The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.

Cureus, 17(2), e79105

View on PubMed ↗Publisher’s paper ↗

Citation

Abdulraheem, Ahmad; Shukri, Dania; Altork, Nadera; Afzal, Usman; Abu-Rumaileh, Mohammed; Meighani, Alireza. (2025). The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report.. Cureus, 17(2), e79105. https://doi.org/10.7759/cureus.79105